Top 20 of HIV Infections

Article title # Publications/# Citations

Prevention of HIV-1 infection with early antiretroviral therapy.

2011: HPTN 052 Study Team; DBurns; DCelentano; SChariyalertsak; YQChen; MSCohen; Gde Bruyn; VElharrar; ... JEron; SHEshleman; MEssex; TRFleming; JGallant; TGamble; SVGodbole; BGrinsztejn; JGHakim; DHavlir; IFHoffman; MCHosseinipour; NKumarasamy; JKumwenda; JMakhema; KHMayer; MMcCauley; SMehendale; LAMills; KNielsen-Saines; JHPilotto; EPiwowar-Manning; HRibaudo; ISanne; BRSantos; SSwindells; TETaha; LWang;

953

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

1995: WChen; DDHo; JMLeonard; MMarkowitz; AUNeumann; ASPerelson;

813

Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

2006: DAltmann; TEAsher; BRBlazar; EBornstein; JMBrenchley; SGDeeks; DCDouek; FMHecht; ... ZKazzaz; OLambotte; ALanday; MMLederman; JNMartin; LJPicker; DAPrice; SRao; BRodriguez; TWSchacker; GSilvestri; LTeixeira-Johnson;

794

Projections of global mortality and burden of disease from 2002 to 2030.

2006: DLoncar; CDMathers;

747

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

1996: GPAllaway; CCayanan; TDragić; YHuang; RAKoup; VLitwin; PJMaddon; SRMartin; ... JPMoore; KANagashima; WAPaxton;

734

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

2009: MOPH-TAVEG Investigators; EAdams; MBenenson; DLBirx; JChiu; SChunsuttiwat; MDe Souza; DPFrancis; ... SGurunathan; JKaewkungwal; CKhamboonruang; JHKim; PKunasol; JGMcNeil; NLMichael; CNamwat; SNitayaphan; RParis; PPitisuttithum; NPremsri; SRerks-Ngarm; MLRobb; DStablein; JTartaglia; PThongcharoen;

720

Antibody neutralization and escape by HIV-1.

2003: JMDecker; BHHahn; HHui; JCKappes; JMKilby; NLKomarova; PDKwong; MANowak; ... MSSaag; MGSalazar; JFSalazar-Gonzalez; GMShaw; SWang; XWei; XWu;

705

Viral dynamics in human immunodeficiency virus type 1 infection.

1995: SBonhoeffer; PDeutsch; EAEmini; SKGhosh; BHHahn; VAJohnson; JDLifson; MANowak; METaylor; XWei;

688

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

2010: CAPRISA 004 Trial Group; QAbdool Karim; SSAbdool Karim; NArulappan; CBaxter; JAFrohlich; TNGengiah; ACGrobler; ... ABKharsany; SMaarschalk; LEMansoor; KPMlisana; MMlotshwa; LMorris; ZOmar; SSibeko; DTaylor;

623

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

1996: DDHo; JMLeonard; MMarkowitz; AUNeumann; ASPerelson;

601

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

2006: RAhmed; MAltfeld; JABrown; HMCoovadia; CLDay; CDePierres; JDuraiswamy; QEichbaum; ... GJFreeman; PJGoulder; DEKaufmann; PKiepiela; PKlenerman; AJLeslie; EWMackey; JDMiller; ZMncube; ESMoodley; SReddy; BDWalker; EJWherry; BZhu;

600

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

2004: PAutissier; MKiessling; CMOwens; MJPerron; JSodroski; MStremlau;

598

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

2000: RHGray; CLi; TLutalo; MOMeehan; TCQuinn; DSerwadda; NSewankambo; FWabwire-Mangen; MJWawer;

586

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

2006: JAbraham; JMBenito; MRBetts; MConnors; SCDe Rosa; PAGoepfert; RAKoup; MMLederman; ... SAMigueles; MCNason; MRoederer; SMWest;

582

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

1995: SKArya; FCocchi; ALDeVico; RCGallo; AGarzino-Demo; PLusso;

579

Adherence to medication.

2005: TBlaschke; LOsterberg;

575

Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.

2006: Centers for Disease Control and Prevention (CDC); BMBranson; JEClark; HHHandsfield; RSJanssen; MALampe; SBLyss; AWTaylor;

574

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

2008: JAAnderson; GSAthreya; TBhattacharya; WABlattner; MPBusch; MSCohen; JMDecker; ELDelwart; ... FGao; BGaschen; EEGiorgi; PAGoepfert; TGrayson; BHHahn; BFHaynes; CJiang; BFKeele; JMKilby; JLKirchherr; BTKorber; HYLee; HLi; DCMontefiori; ASPerelson; KTPham; LHPing; MSSaag; MGSalazar; JFSalazar-Gonzalez; CSeoighe; GMShaw; CSun; RSwanstrom; GDTomaras; SWang; XWei; NWood;

549

Glutamate uptake.

2001: NCDanbolt;

548

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

2009: Protocol G Principal Investigators; DRBurton; PYChan-Hui; SFling; SMFrey; JLGoss; PWHammond; SKaminsky; ... WCKoff; JKLehrman; JLMitcham; MMoyle; OAOlsen; SKPhogat; PPhung; PPoignard; FHPriddy; MDSimek; DWagner; LMWalker; TWrin; TZamb;

528